推荐产品
等级
certified reference material
质量水平
表单
liquid
特点
(Snap-N-Spike®)
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
1.0 mg/mL in acetonitrile
技术
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
应用
clinical testing
包装形式
single component solution
储存温度
−20°C
InChI
1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)
InChI key
PCOBBVZJEWWZFR-UHFFFAOYSA-N
基因信息
human ... KCNQ1(3784) , KCNQ2(3785) , KCNQ3(3786) , KCNQ4(9132) , KCNQ5(56479)
一般描述
Retigabine, also known as ezogabine, is a new antiepileptic drug developed for treatment of partial seizures. The drug is marketed under the trade names Potiga in the US and Trobalt in the EU. This certified solution standard is suitable for use as starting material in calibrators and controls for LC/MS or GC/MS methods in clinical toxicology, forensic analysis, urine drug testing, pain prescription monitoring, or pharmaceutical research applications.
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
警示用语：
Danger
危险分类
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2 - Flam. Liq. 2
储存分类代码
3 - Flammable liquids
WGK
WGK 2
闪点(°F)
42.8 °F - closed cup - Solvent
闪点(°C)
6.0 °C - closed cup - Solvent
法规信息
危险化学品
Ewa Zwierzyńska et al.
Postepy higieny i medycyny doswiadczalnej (Online), 67, 973-981 (2013-10-04)
Retigabine belongs to a new generation of antiepileptic drugs. Its mechanism of action is different from that previously known. Retigabine opens potassium channels of subfamily Kv 7, especially Kv 7.2 and Kv 7.3. The drug enhances GABA-ergic transmission. It is
Sylvain Rheims et al.
Expert review of neurotherapeutics, 12(5), 509-517 (2012-05-04)
Ezogabine/retigabine (RTG) is a novel antiepileptic compound that activates a voltage-sensitive neuronal-specific outward potassium current that decreases neuronal excitability. RTG has been evaluated in three pivotal placebo-controlled randomized trials as adjunctive therapy in adult drug-resistant partial epilepsy. In comparison to
Carl E Stafstrom et al.
Nature reviews. Drug discovery, 10(10), 729-730 (2011-10-01)
Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the U.S. Food and Drug Administration (F.D.A.) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this
Michele Y Splinter
Clinical therapeutics, 34(9), 1845-1856 (2012-08-25)
Ezogabine, also known as retigabine, is a recently approved anticonvulsant medication with a novel mechanism of action. It activates low-threshold voltage-gated potassium channels, leading to hyperpolarization of the membrane potential, stabilization of the resting membrane potential, and suppression of repetitive
Emma D Deeks
CNS drugs, 25(10), 887-900 (2011-09-23)
Retigabine (ezogabine in the US) opens neuronal voltage-gated potassium channels, resulting in resting membrane potential stabilization, neuronal subthreshold excitability control and anticonvulsant effects. The clinical efficacy of adjunctive oral retigabine in adults with inadequately controlled, partial-onset seizures was demonstrated in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门